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Kristin M. Page,1 Lijun Zhang,2 Adam Mendizabal,2 Stephen Wease,2 Shelly Carter,2
Tracy Gentry,3 Andrew E. Balber,3 Joanne Kurtzberg1Graft failure occurs in approximately 20% of patients after unrelated umbilical cord blood transplantation
(UCBT). This could be because of inadequate potency of the cord blood unit (CBU). To this end, we inves-
tigated the impact of graft characteristics on engraftment and survival of 435 primarily pediatric (median age:
5.3 years) patients receiving a single-unit unrelated UCBT after myeloablative conditioning from 2000 to
2008. Pre-cryopreservation (pre-cryo) graft characteristics were provided by the banks. Post-thaw param-
eters were measured on dextran/albumin-washed grafts. Post-thaw recovery of the colony-forming unit
(CFU), a biological assay reflecting functional viability of the cord blood cells was the lowest percent age
(median 21.2%, mean 36.5%) of the pre-cryo value, regardless of the bank of origin. The cumulative inci-
dences of neutrophil and platelet engraftment were 76.9% (95%, confidence interval [CI], 71.3%-82.5%)
and 55% (95% CI, 49.3%-60.7%), respectively. Univariate and separate multivariate models using pre-cryo
and post-thaw datasets including clinical parameters identified predictors of engraftment and survival. In mul-
tivariate modeling, higher CFU dosing was the only pre-cryo graft characteristic predictive of neutrophil (P5
.0024) and platelet engraftment (P5.0063). In the post-thawmodel, CFU dose best predicted neutrophil and
platelet engraftment (both P\ .0001). Comparatively, CD341 and total nucleated cell (TNC) were only
weakly predictive in post-thaw neutrophil and platelet engraftment models, respectively. In conclusion,
CFU dose is a strong independent predictor of engraftment after unrelated UCBTand should be used to as-
sess potency when selecting CBUs for transplantation.
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Using current graft selection criteria, primary graft
failure and engraftment delays are major obstacles to the
overall success of unrelated donor umbilical cord blood
transplantation (UCBT).Up to 20%ofpatients receiving
a UCBT experience primary graft failure [1-4], which
results in part from inadequate potency of their donor
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6/j.bbmt.2011.01.011transplant centers is to base selection of a donor CBU
on total nucleated cell (TNC) dose and human
leukocyte antigen (HLA) matching. This strategy is
based on multiple reports demonstrating that TNC
dose is a critical determinant of engraftment and
survival after unrelated UCBT [1,5-9]. CD341 cell dose
has also been shown, in a smaller number of studies, to
predict engraftment and survival [10-13], but the use
of CD341 as a selection parameter is limited by lack
of pre-cryopreservation (pre-cryo) CD341 enumeration
on a significant proportion of CBUs in the public
banking inventories and lack of standardization and
reproducibility of CD341 enumeration methodology
among banks. In addition, measuring TNC and CD341
cell dose on the CBU before cryopreservation may not
necessarily reflect the overall quality or potency of the
CBU after cryopreservation and storage. Identification
of additional criteria to assess CBU potency should
allow for optimization of selection of CBUs likely to
engraft, improving overall outcomes of unrelatedUCBT.
Biol Blood Marrow Transplant 17:1362-1374, 2011 1363CFUs Strongly Predict Engraftment after UCBTSince performing the first unrelated UCBT in
1993, our center has been integrally involved in the
evolution of the field, transplanting more than 900 pa-
tients with umbilical cord blood (UCB) to date. The
establishment of the Carolinas Cord Blood Bank
(CCBB) at Duke, a member of the National Cord
Blood Inventory (NCBI), through the Cord Blood
Transplantation (COBLT) program in 1997 has al-
lowed us to develop expertise in the collection, pro-
cessing, testing, and banking of UCB for unrelated
donor transplantation. Thus, with dual expertise, we
are well suited to evaluate the role of UCB graft pa-
rameters on engraftment after UCBT as they relate
to characteristics of the graft at collection, after pro-
cessing and before cryopreservation, and after thawing
for infusion into the patient. In this report, we present
a retrospective analysis of unrelated donor UCBT
performed at our center that identifies important graft
parameters influencing engraftment. We show that
the dose of colony-forming units (CFU) is the most
important CBU parameter influencing engraftment,
and that the number of CFUs in a unit is changed
significantly by cryopreservation and thawing. These
results have important implications for understanding
the utility of inventory in public cord blood (CB)
banks. We have also used these results to construct
a metric of CBU potency useful in optimization of
UCB graft selection for transplantation [14].MATERIALS AND METHODS
Study Design and Eligibility
We performed a retrospective analysis of 435 con-
secutive unrelated UCBTs using a single, nonmanipu-
lated CBU after full myeloablative conditioning as
a first transplant between 1/1/00 and 12/31/08. Study
subjects were selected from a pool of consecutive
patients meeting these criteria transplanted at Duke
University Medical Center for a malignancy, bone
marrow failure syndrome, hemoglobinopathy, immu-
nodeficiency, or metabolic disorders. Transplants
were eligible for this analysis if identified technical
graft characteristics, including TNC, mononuclear
cell count (MNC), CD341, and total CFU content,
were available for the CBU before cryopreservation
and after thawing. All patients were enrolled in
a Duke University Medical Center institutional review
board–approved protocol or treatment plan. Written
informed consent was obtained from all patients or le-
gal guardians. Of the patients included in this study,
132 patients were previously reported as part of
the COBLT study [1,2,15], and 10 patients are
enrolled on the current Blood and Marrow
Transplant Clinical Trials Network single versus
double unrelated donor UCBT trial (BMT CTN
0501). A subset of the study population has beenpreviously reported by Prasad et al. [16] (n 5 159)
and in other reports from our center [17-21].
Selection of Donors
Intermediate-resolution typing for HLA class I (A
and B) and high resolution for HLA-DRB1 was used
for initial donor screening. High-resolution HLA typ-
ing was also obtained on the patient and donor for con-
firmatory typing and used for final unit selection. The
CBUwith the highest number of nucleated cells/recip-
ient body weight and closest HLAmatch (minimum 3/
6 HLA loci match) was selected. ABO typing and
information about donor gender, race, and ethnicity
were provided for all units pre-cryopreservation. A
cell dose of .3  107 TNC/kg and a minimum of
a 4/6 HLA match were prioritized for final donor se-
lection whenever possible. Matching for race/ethnicity
and ABO types were also prioritized when feasible.
CBU Collection, Processing, Thawing,
and Infusion
CBUs were collected and processed according
to local bank procedures.Upon selection for transplan-
tation, they were shipped to the Duke Stem Cell
Laboratory (SCL) in a dry shipper that maintained
temperatures below 2150C. Upon receipt at the
SCL, units were removed from the dry shipper and
quickly transferred to a liquid nitrogen freezer where
they were stored under liquid nitrogen until the day
of transplant. One to 2 hours before transplant, all
CBUs were thawed using a modified version of the
dextran/albumin wash per Rubinstein et al. [22]. The
washed cells were resuspended in dextran 40/5% albu-
min in a final volume of the adjusted not to exceed 5
mL/kg of the patient’s body weight. Thirty minutes
prior to CBU infusion, patients were premedicated
with acetaminophen, diphenhydramine, and methyl-
prednisolone. The CBU was infused through the pa-
tient’s central venous line over 15 minutes. Aliquots
(0.5 mL) of the product were obtained after washing
(post-thaw) and analyzed for sterility, TNC,MNC, vi-
ability, CFU, CD31, and CD341 content.
CBU Characteristics
Data were provided by the CB bank supplying the
unit for transplantation as part of routine reporting
procedures. The available data included pre-cryo
TNC, MNC, CD341 cell dose, CFU content, and
cell viability. Post-thaw testing was performed at
Duke SCL using samples obtained after thawing and
washing with dextran/albumin, and included TNC,
MNC, CD341, CFU (total), CD31, and cell viability.
CFU subsets were also enumerated, but not included
in this analysis. ABO typing and microbial cultures
(bacterial and fungal) were provided for all CBUs
pre-cryo and post-thaw.
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TNC and MNC
For CBUs collected and processed by the CCBB,
and all thawed units, TNC counts were obtained on
an automated cell counter (Sysmex K-1000 from
1/00-4/08, Sysmex XE5000 for pre-cryo analysis
from 4/08 to present; Sysmex XS-1000i for post-
thaw analysis from 4/08 to present, Sysmex America,
Inc. Mundelein, IL). Manual differentials were per-
formed by personnel of the CCBB at Duke and Duke
SCL for calculation of the total MNC count, which
was represented by (%lymphocytes 1%monocytes 1
%blasts)  TNC.CD341
Enumeration of CD341 cells was determined by
flow cytometry (ProCOUNT, BD Biosciences, San
Jose, CA). ProCOUNT reagent (20 mL) was added
to 12  75 mm test tubes followed by 50 mL of CB
sample. Samples were diluted with phosphate-
buffered saline/bovine serum albumin (PBS/BSA)
wash (Gibco, Invitrogen, Carlsbad, CA) as needed
for a concentration\4  107 cells/mL. Tubes were
mixed gently and incubated in the dark at room tem-
perature for 15 minutes. Red blood cells (RBCs)
were further lysed using 450 mL of a 1:10 dilution of
FACS Lysing Solution (BD Biosciences, San Jose,
CA) for samples and incubated in the dark at room
temperature for 15 minutes. A 2-laser, 4-color flow
cytometer was used to analyze samples. Results were
analyzed by CellQuest Pro (BD Biosciences) using
ProCOUNT gating strategies.
Precryo CFU progenitor cell assay
CFU progenitor cells, including granulocyte
macrophage (CFU-GM), granulocyte, erythrocyte,
macrophage, and megakaryocyte (CFU-GEMM), and
burst-forming unit erythroid (BFU-E), were enumer-
ated on precryo samples of CB. Initial samples of 2.5 
105 CB cells were removed for testing and diluted
in 0.5-mL Iscove’s modified Dulbecco’s Medium
(IMDM) plus 2% fetal bovine serum (FBS) (StemCell
Technologies, Vancouver, BC,Canada). Cells were fur-
ther diluted by adding 5  104 cells in a total of 0.5 mL
IMDMplus 2%FBS to achieve a final cell count of 2.5
104/mL when mixed with 1.5-mL of MethoCult me-
dium 4434 (StemCell Technologies). Cells were plated
in triplicate (0.5 mL/well) at 1.25  104 cells/well in
24-well tissue culture plates and incubated in a humidi-
fied, 37C, 5%CO2 incubator for 11 to 14 days. Colony
growth was scored by trained personnel using an in-
verted, phase-contrast microscope and reported as the
mean colony count 105 nucleated cells. These num-
bers were then used to calculate the number of progen-
itors in the entire graft by using the pre-cryo TNC.Postthaw CFU progenitor cell assay
CFU progenitors were enumerated on post-thaw
samples of CB obtained at time of unit thaw and a total
of all CFU progenitors were calculated for each graft
infused. From the thawed graft, CB samples containing
4 105 cells were diluted in IMDMplus 2%FBS. A to-
tal of 4 104 cells in 0.1-mL IMDMplus 2%FBSwere
mixed with 0.5 mL of MethoCult medium (4434,
StemCellTechnologies). Cells were plated in duplicate
(0.3mL/well) at 2 104 cells/well in 24-well tissue cul-
ture plates and incubated in a humidified, 37C, 5%
CO2 incubator for 11 to 14 days. Colony growth was
reported as the mean colony count 105 nucleated
cells. Total CFU progenitors were calculated by sum-
ming the mean CFU-GM, CFU-GEMM, and BFU-E
totals for each CB sample and then calculating the total
number of CFU progenitors in the infused graft based
on the TNC in the infused graft.
Conditioning, Graft-versus-Host Disease
Prophylaxis and Supportive Care
Conditioning regimens were based on patient age,
diagnosis, and disease state. Total-body irradiation
(TBI) was used in conditioning for 190 patients
(43.6%). Graft-versus-host disease (GVHD) prophy-
laxis was cyclosporine 1 methylprednisolone (n 5
330, 75.8%) or cyclosporine 1 mycophenolate mofetil
(n5 90, 20.6%)or tacrolimus6mycophenolatemofetil
(n 5 15, 3.6%). All patients were nursed in reverse
isolation rooms under positive pressure and HEPA fil-
tration. Standard prophylaxis was used against pneumo-
cystis carinii, acyclovir for viral, and voriconazole for
fungal infections. Empiric antibiotic treatment was
started with the first febrile episode and continued
through engraftment. Intravenous immune globulin
(500 mg/kg/dose) was administered weekly through
day 100 then monthly through 1 year, then weaned as
tolerated. As prophylaxis against veno-occlusive disease,
a continuous infusion of low-dose heparin was used
through day 28. Patients received transfusions of
leukocyte-depleted, irradiated-packed RBCs and plate-
lets. Granulocyte colony-stimulating factor (G-CSF)
was administered from day 0 until hematopoietic recov-
ery and then was weaned.
Engraftment and GVHD
Neutrophil engraftment was defined as the first
day of 3 consecutive days of an absolute neutrophil
count of $500 donor cells/mm3. Platelet engraftment
was defined as the first day of achieving an untrans-
fused count of $50,000 platelets/mm3 for 7 days.
Confirmation of donor cell chimerism was performed
using fluorescence in situ hybridization (FISH) or
RFLP. Acute GVHD and chronic GVHD (aGVHD,
cGVHD) were scored as the maximum grade in all pa-
tients at the highest level per consensus criteria [23].
Table 1. Patient and Treatment Characteristics of the
Overall Study Population, Cord Blood Units, and Transplants
(N 5 435)
Patient Characteristics Median (Range)
Age, years 5.3 (3 weeks-55.8)
Weight, kg 19.8 (2.7-118.4)
N (%)
Age, >18 years old 43 (9.8)
Gender
Male 268 (61.6)
Female 167 (38.4)
Race/ethnicity
Caucasian 306 (70.3)
Non-Caucasian 129 (29.7)
Diagnosis
Malignant 253 (58.2)
Metabolic 132 (30.3)
Other 50 (11.5)
CMV serostatus
Positive 164 (37.7)
Negative 269 (61.8)
Indeterminate 2 (0.4)
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Pearson’s correlation coefficient was used for corre-
lation analyses between pre-cryo and post-thaw graft
characteristics. Survival probabilities at 180 days and 1
year were estimated using Kaplan-Meier method [24].
Graft and patient characteristics were examined to de-
termine factors predictive of survival using Log rank
test in the univariate analysis, and Cox proportional
hazardsmodel formultivariate analysis.Time toneutro-
phil and platelet engraftment were estimated using the
cumulative-incidence-function method, from patients
surviving past day 14 and treating death, relapse, and
graft failure as competing risks [25]. Relapsewas consid-
ered as a competing risk for engraftment to account
for those patients who relapsed prior to engraftment.
Associations between graft/patient characteristics and
kinetics of neutrophil or platelet engraftment were eval-
uated univariately by Gray’s test [26], and multivariate
analysis was performed using Fine and Gray model
[27] with backward selection. A P value of #.05 was
considered significant.
Graft and patient characteristics examined in both
univariate and multivariate analysis for engraftment
and survival included pre-cryo and post-thaw graft pa-
rameters (TNC, MNC, CD341, and CFU cell doses,
volume collected, bank, etc.), patient characteristics
(age, gender, diagnosis, degree of HLA match, recipi-
ent and unit ethnicity, recipient weight, use of TBI,
GVHD prophylaxis, and cytomegalovirus [CMV] sta-
tus), andmatching status of recipient to unit in terms of
gender, ABO, and ethnicity. Separate multivariate
analysis was performed for pre-cryo and post-thaw
graft parameters whereas clinical characteristics were
evaluated together with graft parameters. Continuous
parameters were categorized by corresponding me-
dians or quartiles. All analyses were completed using
the SAS system, version 9.2, and R, version 2.7.Patient—CBU match
HLA match
6/6 33 (7.6)
5/6 146 (33.6)
#4/6 255 (58.8)
ABO match
Matched 231 (53.1)
Mismatched 204 (46.9)
Gender match
Matched 219 (50.3)
Mismatched 216 (49.7)
Race/ethnicity match
Matched 305 (70.1)
Mismatched 130 (29.9)
Treatment characteristics
Preparative regimen
TBI containing 190 (43.6)
Non-TBI containing 245 (56.4)
GVHD prophylaxis
Cyclosporine/methylprednisolone 330 (75.9)
Cyclosporine/mycophenolate mofetil 90 (20.7)
Tacrolimus-based regimens 15 (3.4)
CMV indicates cytomegalovirus; CBU, cord blood unit; HLA, human
leukocyte antigen; GVHD, graft-versus-host disease; TBI, total-body
irradiation.RESULTS
Patient and Treatment Characteristics
From 2000 to 2008, 435 consecutive patients re-
ferred to our center were treated with unrelated donor
UCBT using a single, nonmanipulated CBU after
a myeloablative preparative regimen. The median age
of the group was 5.3 years (range: 3 weeks to 55.8
years) including 43 adults (.18 years of age; 9.8%).
The median patient weight was 19.8 kg (range: 2.7-
118.4 kg) at time of transplant. Of the 435 patients,
58.2% had malignancies, 61.6% were males, 70.3%
were Caucasian, and 37.7% were CMV seropositive
pretransplant. Patients and donors were matched for
ABO, gender, and race/ethnicity in 53.1%, 50.3%,
and 70.1% of cases, respectively. Patients and CBUs
were matched at 6/6 (7.6%), 5/6 (33.6%), 4/6
(55.9%), or#3/6 (2.9%) HLA loci using antigen-leveltyping atHLA-Class I and allelic typing at HLA-Class
II, DRB1. According to practices at our transplant cen-
ter, which transplants a large number of small children
with inborn errors of metabolism, approximately half
of the patients received non–TBI-containing prepara-
tive regimens, and the majority received cyclosporine-
based GVHD prophylaxis (Table 1).Graft Characteristics
Donor CBUs were obtained from 16 public banks
in the United States. Almost half (46%, n5 199) were
obtained from the CCBB at Duke. The other CBUs
were obtained from theNational Cord Blood Program
(22%, n5 97) or 14 other U.S. CB banks who distrib-
ute CBUs through the National Marrow Donor
Table 2. Characteristics of Transplanted Cord Blood Units
Graft Characteristic
Precryo Post-thaw Median Recovery Post-thaw
Pearson Correlation
Coefficient (r)n Median (Range) n Median (Range) n* %
TNC, 107/kg 434 6.7 (1.4-67.3) 435 5.7 (0.9-50.3) 434 81.1 0.96
MNC, 107/kg 216 2.8 (0.21-30.3) 383 2.1 (0.2-15.1) 197 82.8 0.83
CD34+, 105/kg 381 2.1 (0.1-29.3) 433 1.7 (0.1-18.3) 379 84.5 0.87
CFU, 104/kg 279 19.1 (0-294.0) 435 3.3 (0-105.3) 279 21.2 0.40
TNC indicates total nucleated cell; MNC, mononuclear cell count; CFU, colony-forming unit.
*Refers to n available for paired analysis.
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(19%) units were banked through the COBLT study
funded by the National Heart, Lung, and Blood Insti-
tute. The majority of CBUs were volume reduced and
RBC depleted before cryopreservation; 10 (2%) con-
tained RBCs as they were processed via plasma deple-
tion alone. All CBUs were washed with dextran/
albumin before administration to the patient.
Grafts were characterized pre-cryo and post-thaw
(after washing) to enumerate TNC, MNC, CD341,
and CFU (Table 2). There was good correlation (r .
.9) betweenTNC andMNC in both pre-cryo and post-
thaw datasets. Correlations between CFU and CD341
(r5 .71) and CFU and MNC (r5 .76) were moderate.
Comparison of the pre-cryo and post-thaw values for all
CBUs from all banks showed excellent correlations for
TNC (r 5 .96, P\ .0001) and good correlations for
MNC (r 5 .83, P\ .0001) and CD341 (r 5 .87, P\
.0001). Of note, much weaker correlations were noted
for pre-cryo and post-thaw CFU (r 5 .40, P\ .0001).
The median post-thaw recoveries of TNC, MNC,
CD341, and CFU were 81.1%, 82.8%, 84.5%, and
21.2%, respectively. Similar correlations (TNC r 5
.95, MNC r 5 .83, CD341 r 5 .91, and CFU r5 .37)
were observed when evaluating CBUs both collected
and transplanted at Duke.Impact of Graft and Clinical Characteristics
on Engraftment
Neutrophil engraftment
In the overall study group, neutrophil engraftment
occurred in a median of 26 days (range: 7-104 days)
with an overall probability of neutrophil engraftment
of 76.9% at 42 days (95% confidence interval [95%
CI], 71.3%-82.5%) posttransplant, which is consistent
with previous reports of outcomes ofUCBT [1,2,7,28].
We first examined in univariate analysis the influence
of graft and clinical characteristics on the time to
neutrophil engraftment. In univariate analysis of the
pre-cryo dataset, CFU and CD341 cell doses were
most predictive of engraftment, followed by TNC
and MNC (Table 3 and Figure 1). We also examined
the influence of post-thaw graft characteristics on neu-
trophil engraftment. In univariate analysis of post-thaw
graft characteristics, CFU, followed byMNC,CD341,andTNCdoses were favorably associated with neutro-
phil engraftment; post-thaw CFU dose had the stron-
gest hazard risk (Table 3 and Figure 2). Multiple
clinical variables, most notably recipient pretransplant
CMV serostatus, metabolic disease, and younger age,
were predictive in univariate analysis of neutrophil
engraftment (Supplemental Table S1).
Analysis of neutrophil engraftment
in multivariate analysis
Separate multivariate analyses were performed us-
ing a pre-cryo and post-thaw datasets for neutrophil
engraftment. Clinical characteristics were considered
in all multivariate analyses. In the pre-cryo neutrophil
engraftment model, negative recipient CMV was the
strongest predictor of engraftment followed closely
by higher precryo CFU dose, male donor, and meta-
bolic diagnosis, a group of smaller and younger pa-
tients who generally received higher cell dosed grafts
(Table 4). Post-thaw CFU dose was the most highly
correlated characteristic in the post-thaw multivariate
model followed by metabolic diagnosis and male do-
nor. Recipient CMV, post-thaw MNC, and CD341
doses were predictive of engraftment in the post-
thaw model, but to a much lesser degree (Table 4).
Platelet engraftment
Platelet engraftment, defined as $50,000 platelets/
mm3 untransfused, occurred at a median 134 days
(range: 22-471 days) posttransplant with an overall
probability of 55% at 180 days (95% CI, 49.3%-
60.7%). In univariate analysis of pre-cryo parameters,
patients receiving higher doses (above the median) of
CFU, CD341, and TNC were more likely to engraft
platelets. Higher doses were also associated with more
rapid platelet engraftment (Table 3 and Figure 3).
Pre-cryoMNCdosewas also predictive of overall plate-
let engraftment, but to a lesser degree than the other
graft variables. In the post-thaw dataset, all of the graft
characteristics (TNC, MNC, CD341, and CFU doses)
were predictive of platelet engraftment in univariate
analysis (Table 3 and Figure 4). Multiple clinical vari-
ables were predictive in univariate analysis of platelet
engraftment including recipient CMV status, diagnosis,
race/ethnicity, age, and HLA matching (Supplemental
Table S1).
Table 3. Graft Characteristics Affecting Neutrophil and Platelet Engraftment ($50,000 Platelets/mm3) in Univariate Analysis*
Hazard Ratios (95% CI)
Neutrophil Engraftment
Platelet Engraftment
($50,000 Platelets/mm3)
Pre-cryopreservation graft characteristics
TNC, 107/kg
4.0 or less 1.00 1.00
>4.0-6.7 1.19 (0.91-1.57) 1.26 (0.90-1.78)
>6.7-10.6 1.70 (1.27-2.27), P 5 .0004 1.76 (1.25-2.49), P 5 .0010
>10.6 2.07 (1.53-2.78), P < .0001 2.09 (1.48-2.96), P < .0001
MNC, 107/kg
1.7 or less 1.00 1.00
>1.7-2.8 1.08 (0.76-1.55) 0.97 (0.62-1.51)
>2.8-4.7 1.06 (0.73-1.53) 1.15 (0.74-1.79)
>4.7 2.10 (1.43-3.08), P 5 .0001 1.75 (1.12-2.72), P 5 .0130
CD34+, 105/kg
1.0 or less 1.00 1.00
>1.0-2.1 1.12 (0.84-1.50) 1.50 (1.05-2.14), P 5 .0250
>2.1-3.6 1.56 (1.14-2.14), P 5 .0050 1.64 (1.12-2.40), P 5 .0110
>3.6 2.49 (1.81-3.44), P < .0001 2.39 (1.63-3.50), P < .0001
CFU, 104/kg
10.5 or less 1.00 1.00
>10.5-19.1 1.40 (0.99-1.97) 1.42 (0.92-2.18)
>19.1-33.4 1.54 (1.10-2.15), P 5 .0110 1.94 (1.29-2.91), P 5 .0013
>33.4 2.47 (1.71-3.58), P < .0001 2.37 (1.54-3.63), P < .0001
Post-thaw graft characteristics
TNC, 107/kg
3.4 or less 1.00 1.00
>3.4-5.7 1.29 (0.99-1.68) 1.67 (1.18-2.36), P 5 .0039
>5.7-8.7 1.61 (1.20-2.17), P 5 .0017 2.16 (1.50-3.10), P < .0001
>8.7 2.10 (1.56-2.83), P < .0001 2.43 (1.68-3.51), P < .0001
MNC, 107/kg
1.3 or less 1.00 1.00
>1.3-2.1 1.43 (1.06-1.93), P 5 .0180 1.30 (0.91-1.87)
>2.1-3.5 1.56 (1.17-2.08), P 5 .0023 1.52 (1.08-2.16), P 5 .0180
>3.5 2.36 (1.72-3.24), P < .0001 1.84 (1.27-2.67), P 5 .0013
CD34+, 105/kg
0.9 or less 1.00 1.00
>0.9-1.7 1.35 (1.04-1.78), P 5 .0260 2.02 (1.42-2.88), P 5 .0001
>1.7-3.0 1.69 (1.27-2.25), P 5 .0004 2.21 (1.54-3.17), P < .0001
>3.0 2.32 (1.71-3.14), P < .0001 2.55 (1.76-3.71), P < .0001
CFU, 104/kg
1.3 or less 1.00 1.00
>1.3-3.3 1.51 (1.16-1.95), P 5 .0020 1.57 (1.11-2.20), P 5 .0100
>3.3-6.8 1.90 (1.42-2.53), P < .0001 1.56 (1.09-2.22), P 5 .0150
>6.8 3.64 (2.61-5.07), P < .0001 3.23 (2.24-4.66), P < .0001
TNC indicates total nucleated cell; MNC, mononuclear cell count; CFU, colony-forming unit; CI, confidence interval.
*Significant P values are indicated (as defined by a value of #.05).
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analysis
Multivariate analyses including clinical character-
istics were performed using a pre-cryo and post-thaw
datasets for platelet engraftment. In the pre-cryo
multivariate model of platelet engraftment, higher
CFU dosing, the bank that supplied the CBU, and
negative recipient CMV status were the only signifi-
cant predictors of engraftment (Table 4). Post-thaw
CFU dose had the strongest correlation followed by
metabolic patient diagnosis in the post-thaw multi-
variate platelet engraftment analysis. Receiving a graft
containing a TNC of .5.7  107/kg, negative recip-
ient CMV serostatus, and closer HLA matching were
also predictive of platelet engraftment in the post-
thaw multivariate model with similar hazard ratios
(Table 4).Impact of Clinical and Graft Characteristics
on Overall Survival
The probability of overall survival (OS) in the
study group was 58.9% (95% CI, 54.2%-63.6%) at 1
year. There were 221 patient deaths with primary
causes because of progressive disease (28.5%), graft
failure (5.9%), GVHD (9.1%), infection (31.8 %), or-
gan failure (18.1%), or other causes, including second-
ary malignancy and hemorrhage (6.6%).We examined
factors predictive of OS in univariate and multivariate
analyses at 180 days posttransplant and 1 year (Tables
5 and 6). In the univariate analysis, TNC, CD341, and
CFUwere associated withOS in both the pre-cryo and
post-thaw settings (Table 5). Multiple clinical charac-
teristics were predictive in univariate analysis of overall
survival at both time points, most notably age, diagno-
sis, and recipient CMV serostatus.
Figure 1. Impact of precryo graft characteristics on the probability of neutrophil engraftment. Probability plots are shown for each of the 4 quartiles.
Panels A-D depict the impact of precryo TNC (107/kg recipient weight), MNC (107/kg recipient weight), CD341 (105/kg recipient weight), and
CFU (104/kg recipient weight) doses, respectively, on neutrophil engraftment.
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clinical and graft characteristics, negative recipient
CMV status,metabolic diagnosis and, to a lesser degree,
malegenderwerepredictiveofOSat180days posttrans-
plant. At 1 year, OS in both the pre-cryo and post-thaw
models was strongly impacted by recipient CMV status,
followed by gender andHLAmatch (5/6 or 6/6). Amet-
abolic diagnosis was also predictive in the pre-cryo
model (data not shown), but it was not predictive when
consideringpost-thawgraft characteristics.This is likely
because of the small size of these patients who typically
received higher cell dosed grafts. Although no graft
characteristic strongly predicted OS in multivariate
analysis, CD341 (both precryo and post-thaw) and
CFU (pre-cryo) had weak predictive value at 180 days
and 1 year posttransplant, respectively (Table 6).
How Do These Observations Impact Graft
Selection from a Public CB Bank?
Given the observation that both pre-cryo and post-
thawCFU doses were the graft parameters most closely
correlated with engraftment, we asked what propor-
tions of the inventory (n 5 22,559) of a large public
CB bank (the CCBB at Duke) could deliver acceptable
doses (at or above the median of 19.1  104 CFU/kg
calculated on the pre-cryo CBU content) to theoretical
patients of various weights. As shown in Figure 5,
approximately 49% of the inventory would deliver an
optimal CFU dose for a small patient (20 kg), but
only 2.8% would deliver an adequate dose for a larger
patient (.50 kg). We observed similar findings when
we examined the CCBB inventory more recentlybanked (ie, since 2005 and since 2007). This highlights
the need for continued efforts to increase the inventory
of publically bankedCBUs to provide CBU grafts likely
to engraft to patients undergoing UCBT.DISCUSSION
Primary graft failure and engraftment delays con-
tinue to be significant barriers to the overall success
of unrelated donor UCBT. Both clinical and graft-
related factors may contribute to graft failure. We are
interested in developing methods for measuring graft
potency that will minimize the chance of that a patient
will not engraft because of the graft he or she receives.
Patients that fail to engraft often will engraft when re-
transplantedwith a differentCBU.This highlights that
conventional methods of graft selection, using TNC
and HLA match, do not discriminate CBUs that will
be unlikely to engraft with sufficient sensitivity. In
this large, single-center retrospective study, we present
evidence that the dose of pre-cryo and post-thawCFUs
best predicts CBU engraftment after transplantation
compared to other measures routinely obtained during
the processing, cryopreservation, and thawing of
CBUs. Because of this, we propose that any measure
of CBU potency should give heavy weighting to the
number ofCFUs present in and delivered to the patient
by a selected CBU.
Most transplant centers use TNC/kg dosing for
CBUselection, based onmultiple single-center and reg-
istry series demonstrating strong correlation with cell
dosing and engraftment [4,6,7,9]. With this approach,
Figure 2. Impact of postthaw graft characteristics on the probability of neutrophil engraftment. Probability plots are shown for each of the 4 quartiles.
Panels A-D depict the impact of post-thaw TNC (107/kg recipient weight), MNC (107/kg recipient weight), CD341 (105/kg recipient weight), and
CFU (104/kg recipient weight) doses, respectively, on neutrophil engraftment.
Biol Blood Marrow Transplant 17:1362-1374, 2011 1369CFUs Strongly Predict Engraftment after UCBThowever, approximately 20% of patients still fail to
engraft. In this report, which evaluated an expanded
set of graft characteristics in a patient group receiving
CBUs delivering higher cell doses, we found that
neither pre-cryo nor post-thaw TNC dose correlated
with neutrophil engraftment in the multivariate
analysis, although post-thaw TNC was predictive inTable 4. Positive Predictors in Multivariate Analyses of Neutrophil
Characteristic Favorable Characteristic
Neutrophil engraftment precryo model†
Recipient CMV Negative
CFU >19.1  104/kg
Unit gender Male
Diagnosis‡ Metabolic
Neutrophil engraftment post-thaw model§
CFU >3.3  104/kg
Diagnosis Metabolic
Unit gender Male
MNC >2.1  107/kg
Recipient CMV Negative
CD34+ >1.7  105/kg
Platelet engraftment precryo model
Recipient CMV Negative
CFU >19.1  104/kg
Bank CCBB
Platelet engraftment post-thaw model
CFU >3.3  104/kg
Diagnosis Metabolic
Recipient CMV Negative
TNC >5.7  107/kg
HLA match 5/6 or 6/6
HR indicates hazard ratio; CI, confidence interval; CMV, cytomegalovirus; CFU
ated cell; HLA, human leukocyte antigen.
*Significant P values were defined as a P value of # .05.
†Precryo model included clinical characteristics and precryo graft characteris
‡Diagnosis refers to malignancy versus metabolic versus other.
§Post-thaw models considered clinical characteristics and post-thaw graft charthe platelet engraftment model. This also held true
when conventional TNC quartiles were considered
(Supplemental Table S2). Post-thaw MNC dose was
predictive in multivariate analysis of neutrophil engraft-
ment, but was not predictive of platelet engraftment.
Ideally, a measure of CBU potency should predict
both neutrophil and platelet engraftment.and Platelet Engraftment
HR (95% CI) P Value*
1.65 (1.23-2.20) .0008
1.49 (1.15-1.93) .0024
1.49 (1.16-1.93) .0020
1.47 (1.11-1.94) .0064
1.70 (1.34-2.14) <.0001
1.55 (1.21-1.97) .0004
1.45 (1.15-1.83) .0016
1.43 (1.11-1.85) .0060
1.34 (1.05-1.71) .0190
1.30 (1.01-1.67) .0400
1.96 (1.38-2.70) .0001
1.56 (1.13-2.15) .0063
1.54 (1.06-2.23) .0240
1.66 (1.29-2.13) .0007
1.58 (1.20-2.07) .0010
1.44 (1.08-1.91) .0120
1.43 (1.11-1.84) .0062
1.39 (1.07-1.79) .0130
, colony-forming unit; MNC, mononuclear cell count; TNC, total nucle-
tics.
acteristics.
Figure 3. Impact of precryo graft characteristics on the probability of platelet engraftment. Probability plots are shown for each of the 4 quartiles.
Panels A-D depict the impact of precryo TNC (107/kg recipient weight), MNC (107/kg recipient weight), CD341 (105/kg recipient weight),
and CFU (104/kg recipient weight) doses, respectively, on platelet engraftment.
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ported in several studies as being an important
predictor of engraftment [10-13]. Some transplant
centers utilize the CD341 cell dose in CBU selection
recognizing that significant interlaboratory variability
exists [28,29]. In our series, post-thaw CD341 dose
was a significant predictor of neutrophil engraftment
in multivariate analysis (P 5 .04), but to a lesser
degree than post-thaw CFU (P \ .0001). CD341
dose did not correlate with platelet engraftment, but
did correlate weakly with OS.
In this large, single-center series, CFU dose was
most closely associated with both neutrophil and
platelet engraftment among the graft parameters con-
sidered in a multivariate model. The importance of
CFU dosing was previously recognized in a report
from the New York Blood Center in 2001 showing
that pre-cryo CFU dose was more closely correlated
with engraftment of both neutrophils and platelets
than TNC [30]. In a smaller series of 42 patients trans-
planted from 1995 to 2001, CFU-GM was the only
graft characteristic impacting OS (P 5 .003) and
event-free survival (EFS) (P5 .02) [31]. Another study
more recently showed that post-thaw CFU-GM along
with TNC and CD341 cell dose correlated with the
kinetics of neutrophil engraftment, but only CFU-
GM dose correlated with platelet engraftment [32].
This report also confirms our earlier observations
reported by Prasad et al. [16] demonstrating that
post-thaw CFU dose had the highest correlation
with survival and engraftment after UCBT in a series
of 159 young pediatric patients with inherited meta-bolic disease. In this series, a post-thaw CFU dose
above 5.7 104/kg was associated with the most favor-
able outcomes. Our findings in this larger series of pre-
dominately pediatric patients (\10% were older than
18 years old), many with inherited metabolic diseases,
confirm that CFU dose is a strong predictor of engraft-
ment. However, the pre-cryo CFU dose was only
weakly predictive of OS, which we believe is because
of insufficient power to detect differences in OS. Fur-
ther analysis of an adult dataset should be performed to
confirm these findings and define dosing threshold for
an older population.
HLA has been well described previously as an im-
portant predictor of engraftment and OS. The current
standard of CBU selection matches at the antigen level
for HLA-A and -B and at the allelic level for HLA-
DRB1. In addition to functioning as an independent
variable, there is some evidence that there is mutual in-
teraction betweenHLA and TNC. Gluckman et al. [9]
suggested that HLA mismatching can be overcome by
higher TNC. Eapen et al. [33] also analyzed the inter-
action betweenHLAmatching and cell dose. Although
no differences were observed for fully matched or
2-antigen mismatch UCBT, higher cell dose defined
as .3.0  107/kg in 1-antigen mismatched UCBT
showed improved neutrophil engraftment compared
to lower cell dose with the same mismatch. In a recent
large series from Barker et al. [4], patients receiving
a 6/6 matched CBU regardless of TNC had lower
transplant-related mortality, followed by patients re-
ceiving a 1-mismatched unit with a TNC of $2.5 
107/kg or a 2-mismatched unit with a TNC of$5.0 
Figure 4. Impact of post-thaw graft characteristics on the probability of platelet engraftment. Probability plots are shown for each of the 4 quartiles.
Panels A-D depict the impact of post-thaw TNC (107/kg recipient weight), MNC (107/kg recipient weight), CD341 (105/kg recipient weight), and
CFU (104/kg recipient weight) doses, respectively, on platelet engraftment.
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in patients receiving a 1-mismatched unit with a
TNC of 2.5-4.9 107/kg compared to patients receiv-
ing a 2-mismatched CBU that delivered a TNC of
$5.0  107/kg. We found HLA matching was predic-
tive of platelet but not neutrophil engraftment in
multivariate analysis. HLA matching was also predic-
tive of OS at 1 year, but not of earlier survival (day
180). Thus, although our findings support the role of
HLA in outcomes after UCBT, the effects were less
strong than those detected in other studies and less
strong than graft-related parameters in our study.
Given the strong correlation of CFU dose with en-
graftment, we asked whether the current inventory in
a large public CB bank would provide adequate dosing
of CFUs for various patient weights. Although there
appears to be a sufficient number of potential units
available for smaller patients, there were very few units
providing more than 19.1  104/kg CFUs among
larger patients. To overcome this issue, additional em-
phasis may need to be placed on assessing CFU growth
on the postprocessed CBU to expand the inventory to
include more potent units. Consideration of the CFU
growth in unit selection is appropriate.
Neither the existing Health Resources and Ser-
vices Administration (HRSA) standards for banking
CBUnor the final U.S. Food andDrug Administration
(FDA) guidance setting out standards for units in-
tended for allogeneic UCBT specify that quantitative
CFU assays be performed to characterize CBU dosing.
Our results demonstrate that measurements of pre-
cryo and post-thaw CFU doses are likely to contributestrongly to an improved assay for the potency of
a CBU. However, this assay is difficult to standardize,
and interlaboratory variability is an issue [34-36]. In
this regard, our study, which presents the largest
examination of CFUs to date, benefitted from having
a large, single-center dataset. Additionally, at our
center, consistent personnel have performed almost
half of the pre-cryo CFUs and all of the post-thaw
CFUs during the duration of the study, which,
perhaps, allowed for these findings to emerge. Post-
thaw CFU measurements reflect potential damage to
the CBU during cryopreservation, shipping to
a transplant center, and thawing. Indeed, our data
show that only about 20% of the CFU in a CBU
typically survive banking, shipping, thawing, and
washing using standard clinical techniques. Because
we noticed this phenomenon also in units that were
not shipped (ie, collected, processed, banked by the
CCBB and thawed at Duke SCL), the contribution
of shipping to cell loss does not appear to be
extensive. Although reports of CFU recoveries are
limited, our observation is similar to Wagner et al.
[37], who reported 89% loss compared to pre-cryo
for 20 thawed units transplanted at their center. The
low CFU recovery in this study is contradictory to
the excellent post-thaw clonogenic potential observed
by Broxmeyer et al. [38], who has been following the
stability of progenitor cell growth from a single cord
over more than a decade, but this cord was processed,
cryopreserved, and thawed under different conditions
than those used for standard CB banking. Alonso
et al. [39] noted a median of 76% CFU recovery in
Table 5. Positive Graft Characteristics Predictive of Overall Survival (OS) at 180 Days and 1 Year Posttransplant in Univariate
Analysis
OS at Day 180 OS at 1 Year
Hazard Risk (95% CI), P*
Pre-cryopreservation graft characteristics
TNC, 107/kg
4.0 or less 1.00 1.00
>4.0-6.7 0.79 (0.52-1.21) 0.84 (0.58-1.23)
>6.7-10.6 0.53 (0.33-0.85), P 5 .0081 0.57 (0.37-0.87), P 5 .0089
>10.6 0.47 (0.29-0.76), P 5 .0024 0.54 (0.35-0.82), P 5 .0039
MNC, 107/kg
1.7 or less 1.00 1.00
>1.7-2.8 1.21 (0.60-2.42) 1.45 (0.79-2.68)
>2.8-4.7 0.87 (0.42-1.84) 1.07 (0.56-2.04)
>4.7 0.72 (0.33-1.56) 0.71 (0.35-1.44)
CD34+, 105/kg
1.0 or less 1.00 1.00
>1.0-2.1 0.63 (0.39-1.01) 0.65 (0.43-1.01)
>2.1-3.6 0.55 (0.33-0.92), P 5 .0218 0.62 (0.40-0.98), P 5 .0399
>3.6 0.41 (0.24-0.71), P 5 .0013 0.54 (0.34-0.86), P 5 .0088
CFU, 104/kg
10.5 or less 1.00 1.00
>10.5-19.1 0.83 (0.47-1.47) 0.82 (0.49-1.38)
>19.1-33.4 0.41 (0.21-0.80), P 5 .0094 0.55 (0.32-0.95), P 5 .0317
>33.4 0.63 (0.35-1.14) 0.64 (0.38-1.09)
Post-thaw graft characteristics
TNC, 107/kg
3.4 or less 1.00 1.00
>3.4-5.7 0.52 (0.34-0.81), P 5 .0034 0.61 (0.42-0.89), P 5 .0109
>5.7-8.7 0.52 (0.33-0.81), P 5 .0042 0.51 (0.34-0.77), P 5 .0013
>8.7 0.39 (0.24-0.62), P 5 .0001 0.45 (0.29-0.68), P 5 .0002
MNC, 107/kg
1.3 or less 1.00 1.00
>1.3-2.1 0.84 (0.52-1.36) 0.99 (0.64-1.54)
>2.1-3.5 0.71 (0.44-1.16) 0.82 (0.53-1.28)
>3.5 0.62 (0.37-1.04) 0.73 (0.46-1.17)
CD34+, 105/kg
0.9 or less 1.00 1.00
>0.9-1.7 0.61 (0.39-0.93), P 5 .0223 0.61 (0.41-0.90), P 5 .0126
>1.7-3.0 0.44 (0.28-0.71), P 5 .0008 0.45 (0.29-0.69), P 5 .0003
>3.0 0.44 (0.27-0.70), P 5 .0006 0.54 (0.36-0.81), P 5 .0030
CFU, 104/kg
1.3 or less 1.00 1.00
>1.3-3.3 0.83 (0.53-1.29) 0.89 (0.60-1.32)
>3.3-6.8 0.84 (0.54-1.31) 0.84 (0.57-1.25)
>6.8 0.46 (0.28-0.771), P 5 .0033 0.52 (0.33-0.81), P 5 .0042
TNC indicates total nucleated cell; MNC, mononuclear cell count; CFU, colony-forming unit; CI, confidence interval; OS, overall survival.
*Significant P values are indicated (as defined by a value of #.05).
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although details of the thawing and post-thaw CFU
methods were not described. We believe that the
data from our larger dataset showing low CFU recov-
ery are accurate and that it is the best measure of CBU
potency. The loss of CFU post-thaw is likely explained
by damage incurred by the CBU during cryopreserva-
tion, long-term storage, and thawing. Further consid-
eration of this finding is warranted.
The post-thaw CFU is an important reflection of
the overall potency health of the CBU transplanted
into patients. At our institution, we use the following
strategy for patients undergoing UCBT. At time of
initial unit selection, an additional backup unit is iden-
tified, typed, and reserved for the patient. For all trans-
plants, CFUs are performed on a sample of the thawed
transplant product on day 0 with results available onday 14-16 posttransplant. If CFUs do not grow but the
patient is engrafting, no action is taken. If CFUs do
not grow and the patient is aplastic, the availability of
a second unit is confirmed, and the patient is monitored
more closely. If count recovery has not occurred by day
42 posttransplant, we perform a bone marrow biopsy
and aspirate to determine cellularity and to document
donor chimerism. In the cases where graft failure has
been documented, we proceed to a second transplant
using a reduced-intensity conditioning regimen.
Post-thawCFU dose was a very strong predictor of
engraftment, suggesting that measurement of post-
thaw CFU dose, or a more reliable surrogate, should
be an important part of graft selection. However, the
CFU assay is limited by a long readout time and issues
with standardization between centers. Development
of shorter CFU assays and automatic methods for
Table 6. Predictors Impacting Overall Survival (OS) at 180 Days and 1 Year Posttransplant in Multivariate Analysis
Characteristic Risk Factor* HR (95% CI) P Value†
Precryo model of OS at 180 days
Recipient CMV Positive 2.11 (1.45-3.05) <.0001
CD34+, 105/kg #2.1  105/kg 1.55 (1.06-2.26) .0244
Post-thaw model of OS at 180 days
Recipient gender Female 1.40 (1.00-1.97) .0490
Diagnosis‡ Malignant 1.74 (1.11-2.74) .0168
Recipient CMV Positive 1.72 (1.22-2.43) .0021
CD34+, 105/kg #1.7  105/kg 1.47 (1.03-2.10) .0340
Precryo model of OS at 1 year
Recipient gender Female 1.76 (1.19-2.60) .0050
HLA match§ #4/6 1.92 (1.23-2.94) .0033
Recipient CMV Positive 2.04 (1.37-3.03) .0005
CFU, 104/kg #19.1  104/kg 1.49 (1.01-2.22) .0471
Post-thaw model of OS at 1 year
Diagnosis Malignant 1.73 (1.18-2.55) .0054
HLA match§ #4/6 1.44 (1.04-2.00) .0282
Recipient CMV Positive 1.94 (1.43-2.64) <.0001
Recipient gender Female 1.39 (1.03-1.87) .0329
CMV indicates cytomegalovirus; CFU, colony-forming unit; HR, hazard ratio; CI, confidence interval.
*Risk refers to increased risk of death.
†Significant P values are indicated (as defined by a value of < or 5.05).
‡Diagnosis refers to malignant versus metabolic versus other.
§HLA (human leukocyte antigen) match #4/6 versus 5/6 or 6/6.
Biol Blood Marrow Transplant 17:1362-1374, 2011 1373CFUs Strongly Predict Engraftment after UCBTenumeration are being investigated to address these
limitations. Additionally, CFUs could be assayed
on an attached segment prior to release from the CB-
bank. Previous reports have correlated CFU content
from an attached sample with the overall thawed
graft [40,41]. At our institution, we have developed
a potency assay, including CFU, measured on the
attached segment. We are currently studying whether
potency measured on an attached segment correlates
with engraftment and recoveries of TNC, CD341,
and CFU from the actual transplant bag. We
hypothesize the assay will be predictive of outcomes
after unrelated donor UCBT and would be used to
evaluate potency prior to final unit selection. Such
innovations, coupled with development of metrics for
potency based on the most important graft parameters
influencing engraftment that we have identified,
should help reduce CBU-related graft failure.Figure 5. Availability of CBUs in a large public bank (n 5 22,559),
which contain high CFU cell doses for various patient weights. For var-
ious theoretical patient weights, we have presented the percentage of
CBUs available in a large, public cord blood bank (Carolinas Cord Blood
Bank at Duke). CBUs all met criteria for banking as specified by the
National Cord Blood Inventory.ACKNOWLEDGMENTS
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